176 related articles for article (PubMed ID: 20464428)
1. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS.
Atkinson MA; Martz K; Warady BA; Neu AM
Pediatr Nephrol; 2010 Sep; 25(9):1699-706. PubMed ID: 20464428
[TBL] [Abstract][Full Text] [Related]
2. Anemia and risk of hospitalization in pediatric chronic kidney disease.
Staples AO; Wong CS; Smith JM; Gipson DS; Filler G; Warady BA; Martz K; Greenbaum LA
Clin J Am Soc Nephrol; 2009 Jan; 4(1):48-56. PubMed ID: 19056614
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.
Seliger SL; Zhang AD; Weir MR; Walker L; Hsu VD; Parsa A; Diamantidis CJ; Fink JC
Kidney Int; 2011 Aug; 80(3):288-94. PubMed ID: 21389972
[TBL] [Abstract][Full Text] [Related]
4. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
[TBL] [Abstract][Full Text] [Related]
5. Transfusion burden among patients with chronic kidney disease and anemia.
Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
[TBL] [Abstract][Full Text] [Related]
6. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.
Penne EL; van der Weerd NC; Grooteman MP; Mazairac AH; van den Dorpel MA; Nubé MJ; Bots ML; Lévesque R; ter Wee PM; Blankestijn PJ;
Clin J Am Soc Nephrol; 2011 Feb; 6(2):281-9. PubMed ID: 21030579
[TBL] [Abstract][Full Text] [Related]
7. Anemia and growth status in pediatric patients receiving maintenance dialysis after a failed renal transplant course: an NAPRTCS report.
Goldstein SL; Mattoo TK; Morgenstern B; Martz K; Stablein D; Talley L
Pediatr Transplant; 2007 Mar; 11(2):201-4. PubMed ID: 17300501
[TBL] [Abstract][Full Text] [Related]
8. Hemoglobin differences by race in children with CKD.
Atkinson MA; Pierce CB; Zack RM; Barletta GM; Yadin O; Mentser M; Warady BA; Furth SL
Am J Kidney Dis; 2010 Jun; 55(6):1009-17. PubMed ID: 20418001
[TBL] [Abstract][Full Text] [Related]
9. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
10. Effects of changes in adult erythropoietin dosing guidelines on erythropoietin dosing practices, anemia, and blood transfusion in children on hemodialysis: findings from North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS).
Twichell SA; Hunt EAK; Martz K; Somers MJG;
Pediatr Nephrol; 2020 Feb; 35(2):297-303. PubMed ID: 31709464
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes of children with stage 3-5 chronic kidney disease.
Mong Hiep TT; Ismaili K; Collart F; Van Damme-Lombaerts R; Godefroid N; Ghuysen MS; Van Hoeck K; Raes A; Janssen F; Robert A
Pediatr Nephrol; 2010 May; 25(5):935-40. PubMed ID: 20148340
[TBL] [Abstract][Full Text] [Related]
13. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality].
Nakamura Y; Tsuchiya K; Nitta K; Ando M
Nihon Jinzo Gakkai Shi; 2011; 53(1):38-45. PubMed ID: 21370576
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
16. Etiology and pediatric chronic kidney disease progression: Taiwan Pediatric Renal Collaborative Study.
Chiou YY; Lin CY; Chen MJ; Chiou YH; Wang YF; Wang HH; Tain YL; Chou HH
J Formos Med Assoc; 2016 Sep; 115(9):752-63. PubMed ID: 26320397
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
18. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
19. Association between clinical risk factors and progression of chronic kidney disease in children.
Staples AO; Greenbaum LA; Smith JM; Gipson DS; Filler G; Warady BA; Martz K; Wong CS
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2172-9. PubMed ID: 20813855
[TBL] [Abstract][Full Text] [Related]
20. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
